Anti-viral Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Anti-viral Therapeutics Market is segmented By Mechanism of Action (Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Others), By Application (HIV, Hepatitis, Herpes Simplex Virus, Influenza, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-commerce), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Anti-viral Therapeutics Market Size

Anti-viral Therapeutics Market size was valued US$ 51.72 billion in 2021 and is estimated to reach US$ 70.83 billion by 2031, growing at a CAGR of 4.6% during the forecast period (2024-2031).

Antiviral drugs are a class of medication, which are used in treating viral infections, and most antivirals are used for specific viral infections. Antiviral drugs are sold prescription-based only and are different from antibiotics, which fight against bacterial infections. Unlike most antibiotics, antiviral medication does not destroy the target pathogen, but instead, they obstruct the development. Most antiviral drugs currently available are to help deal with herpes viruses, HIV, influenza A, and B viruses, and hepatitis B, and C viruses. Moreover, researchers are working on expanding the range of antivirals to other families of pathogens.

Anti-viral Therapeutics Market Summary

For More Insights Request Free Sample

Anti-viral Therapeutics Market Trends

The anti-viral therapeutics market growth is driven by several factors including, the rising incidence of patients with viral infections, increasing awareness on viral infections and treatments, novel technological advancements, and various new product launches.

Increasing prevalence of viral infections and rising product launches are expected to drive the market growth.

The global market for the antiviral therapeutics is primarily driven by the growing incidents of viral infections among populations. According to UNAIDS, in 2021, there were an estimated 38.4 million people [33.9 million–43.8 million] worldwide living with HIV/AIDS, of which 28.7 million were taking antiretroviral therapy, and an estimated 1.5 million individuals became newly infected with HIV. According to the World Health Organization (WHO) study report 2022, an estimated 354 million people are living with hepatitis B virus infection and in 2019, hepatitis B resulted in 820 000 deaths. WHO estimated that 58 million people are infected with hepatitis C worldwide, of which 1.5 million new cases are diagnosed every year.

Moreover, strong R&D, increasing product launches for antiviral drugs coupled with the increasing awareness on viral infections and their treatments are of the key drivers in the antiviral therapeutics market growth. For instance, in Mar 2022, ViiV Healthcare, HIV specialist company owned by GSK, Pfizer and Shionogi announced the approval of Cabenuva (cabotegravir, rilpivirine) for treating HIV-1 in adolescents that are virologically suppressed, at least 35 kg weight and aged 12 years or older with stable antiretroviral regimen and no treatment failure history.

Strong pipelines are also going to drive the growth of antiviral therapeutics market. For instance, in May 2019, Atriva Therapeutics GmbH announced the first dose up of its lead drug candidate ATR-002 in a Phase I clinical trial, marks the start of the clinical development of a novel host-targeted approach to treating influenza virus infections.

High cost associated with anti-viral therapeutics is expected to hamper the market growth.

The patent expiration of blockbuster drugs and the high cost of antiviral therapeutics may hinder market progress. According to a study published on Apr, 2021, titled “Estimated lifetime HIV related medical costs in the United States” the average lifetime medical cost related to HIV is around $1,079,999 for diagnosis delay of around 3 years. If discounted 3% it costs around $420,285.

Industry Analysis

The global anti-viral therapeutics market provides in-depth analysis of the market based on various industry factors such as porter’s five forces, regulatory analysis, supply chain analysis, pricing analysis, product innovations and patent analysis.

Anti-viral Therapeutics Market Segment Analysis

Human immunodeficiency virus segment is expected to hold the largest market share in global anti-viral therapeutics market

By application, the global antiviral therapeutics market is segmented into HIV, hepatitis, herpes simplex virus, influenza, and others. The HIV application holds the largest market share owing to its growing prevalence worldwide and an increasing number of drug launches coupled with several drugs currently in the pipeline. According to UNAIDS, in 2021, there were approximately 1.5 million people [1.1 million–2.0 million] who became newly infected with HIV worldwide and nearly 21.7 million people of the total 36.9 million people living with HIV/AIDS were receiving antiretroviral therapy. For instance, in 2020, there were around 30 drugs including Trogarzo, Biktarvy, Delstrigo, and Symtuza that have been approved by the FDA for the treatment of HIV. For instance, in Jul 2022, Rukobia (fostemsavir) an anti-retroviral medicine received approval from United States Food and Drug Administration. This is a novel medication that is used for treatment of adults with HIV who after multiple therapies and medications for HIV infection can’t be treated successfully due to the intolerance, resistance and safety issues. However, hepatitis application is anticipated to show significant market growth, increasing R&D expenditure by key players, and approval of combination antiviral therapies.

By mechanism of action, the global antiviral therapeutics market is segmented into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. The reverse transcriptase inhibitor segment held the most significant market share owing to its high demand and broad product range for the treatment of HIV.

Anti-viral Therapeutics Market Geographical Share

North America region holds the largest market share in the global anti-viral therapeutics market

As per the research study, the global market is divided into majorly five regions such as North America, South America, Europe, the Middle East, Africa, Asia Pacific, and the Rest of the world.

North America accounts for the largest share in the global antiviral therapeutics market and is mainly attributed to the growing prevalence of HIV, hepatitis infections, and influenza in the region. According to the CDC in 2020, an estimated 30,635 people became newly infected with HIV in the US, and approximately 1.1 million people in the US are living with HIV. CDC reported a total of 3,218 cases of acute hepatitis B, with an overall incidence rate of 1.0 cases per 100,000 population and CDC estimates that 800,000 to 2.2 million people in the United States have chronic hepatitis B. Moreover, the advanced regional healthcare infrastructure, high level of drug development, presence of established market players, rise in healthcare expenditure, and high investment in R&D activities by them are likely to boost the North America antiviral therapeutics market growth.

Asia Pacific is registering the fastest CAGR due to the increasing number of manufacturers and key market players in this region. Various novel technological advancements and latest product launches are taking place in countries such as India, China, and Japan. This factor will drive the growth of market in this region. For instance, in May 2022, ViiV Healthcare, HIV specialist company owned by GSK with Pfizer announced that Vocabria (cabotegravir injections) got approved by Ministry of Health, Labour and Welfare in Japan. Vocabria is used in combination with Rekambys (rilpivirine, long-acting injectable) and Edurant of Johnson & Johnson for treatment of human immunodeficiency virus 1 (HIV-1).

Anti-viral Therapeutics Market Companies and Competitive Landscape

The key players in the global anti-viral therapeutics market include Roche, Gilead Sciences, GlaxoSmithKline, Bristol-Myers Squibb, Johnson & Johnson and Merck.

Companies are focusing on key strategies such as collaboration, acquisitions, and product launches which are boosting the growth of the market globally. For instance,

• In Jul 2022, ViiV Healthcare, HIV specialist company oened by GSK and Pfizer announced its license agreement for cabotegravir long-acting related patents with Medicines Patent Pool to provide access in low income, least developed and Sub-Saharan African countries for pre-exposure prophylaxis of HIV. 
• In Jan 2021, Roche announced the approval of its product Xofluza (baloxavir merboxil) by European Commission. Xofluza is used for treating uncomplicated influenza in adults and patients ages more than 11 years and it can also be used for influenza post-exposure prophylaxis.
• In June 2019, Cidara Therapeutics Inc., a biotechnology company developing novel anti-infectives including immunotherapies, announced that new data from studies of CB-012, its Cloudbreak antiviral Fc-conjugate (AVC) candidate for influenza. CB-012 is the first AVC candidate generated by Cidara’s Cloudbreak anti-infective immunotherapy platform.
• In April 2019, the US FDA approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of HIV-1 infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato. This is the first FDA-approved two-drug, FDC regimen for HIV-infected adults who have never received treatment for HIV.

Global Anti-viral Therapeutics Market – Key Companies to Watch

F. Hoffmann La-Roche AG:

Overview: Roche is a healthcare company that provides in-vitro diagnostics and supplies solutions that are innovative as well as transformative in various crucial disease areas. Working in two divisions: Pharmaceuticals and diagnostics. It was established in 1896 and is headquartered in Basel, Switzerland.

Product Portfolio:

Copegus (ribavirin): Copegus is anti-viral medicine that is used for treating hepatitis C virus infected patients that have not undergone interferon alpha treatment and compensated liver disease. It is used in combination with other medication products in adults or children more than 5 years of age.  

Key Developments: In Aug 2022, Roche announced the approval of Xofluza a new drug application by U.S. Food and Drug Administration for treating acute uncomplicated influenza in patients symptomatic for less than 48 hours and aged around 5 to 11 years. This is the 1st oral single dose medicine for influenza approved for children of this age group and can also be for influenza post-exposure prophylaxis.

The global anti-viral therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.